SU 5416 is a vascular endothelial growth factor receptor blocker that may induce severe pulmonary hypertension if combined with chronic hypoxia. Angiogenesis inhibitor used for deep penetration into tumor tissues.
SU 516 was used to study the mechanism of development of cerebral vasculature in zebrafish hindbrain.3 It was used to study the pulmonary vascular remodeling in response to hypoxia in mouse model of pulmonary arterial hypertension.4
SU 5416 is a vascular endothelial growth factor receptor blocker that may induce severe pulmonary hypertension if combined with chronic hypoxia. Angiogenesis inhibitor used for deep penetration into t
umor tissues.
ChEBI: Semaxanib is an oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group. It has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an angiogenesis modulating agent. It is a member of pyrroles, a member of oxindoles and an olefinic compound. It is functionally related to a 3-methyleneoxindole.
Inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET. Displays no activity against EGFR, HER2, IGF1R and PDGFR. Inhibits tumor vascularization and growth of multiple tumor types.
SU 516 inhibits the activity of neuronal nitric oxide synthase and protects the neuronal cells from nitric oxide-mediated neurotoxicity.1 It also acts an agonist of aryl hydrocarbon receptor and is an effective clinical agent for treating autoimmune diseases and transplant rejection.2
